Hummingbird Bioscience, a Singapore-based clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, closed a US$125m Series C financing round.
The round was led by Novo Holdings, with participation from new investors including Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management and existing investors SK Inc, Heritas Capital, and Mirae Asset Venture Capital. Kenneth Harrison, Partner, Novo Ventures, along with Dan Estes, General Partner, Frazier Healthcare Partners, and Kiel Kim, Vice President, SK Inc., will join Hummingbird’s board of directors.
The company intends to use the funds to advance the clinical development of its lead assets including HMBD-001, a HER3 antibody for NRG1-fusion and HER3-driven tumors, and HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors, expand the capabilities of its proprietary Rational Antibody Discovery platform and progress the development of its next-generation pipeline of precision therapeutics including HMBD-009, a BCMA-TACI dual-specific T cell engager.
Led by Piers Ingram, Chief Executive Officer and co-founder, Hummingbird Bioscience is an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes.
Enabled by a proprietary Rational Antibody Discovery platform, the company discovers and engineers precision therapies against optimal yet elusive epitopes that have not been drugged, unlocking novel mechanisms of action. Hummingbird Bioscience is advancing a rich pipeline of first- and best-in-class precision therapies in oncology and autoimmunity, in collaboration with global partners in academia and industry.